Literature DB >> 26294736

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.

Cristina Pérez1, Julia González-Rincón2, Arantza Onaindia3, Carmen Almaráz1, Nuria García-Díaz1, Helena Pisonero1, Soraya Curiel-Olmo1, Sagrario Gómez2, Laura Cereceda1, Rebeca Madureira1, Mercedes Hospital4, Dolores Suárez-Massa5, José L Rodriguez-Peralto6, Concepción Postigo7, Alicia Leon-Castillo3, Carmen González-Vela3, Nerea Martinez1, Pablo Ortiz-Romero7, Margarita Sánchez-Beato2, Miguel Á Piris8, José P Vaqué9.   

Abstract

Entities:  

Keywords:  CTCL; JAK mutations; JAK/STAT; molecular diagnostics; ruxolitinib; targeted therapy

Mesh:

Substances:

Year:  2015        PMID: 26294736      PMCID: PMC4825308          DOI: 10.3324/haematol.2015.132837

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Authors:  Patrick J Lupardus; Mark Ultsch; Heidi Wallweber; Pawan Bir Kohli; Adam R Johnson; Charles Eigenbrot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

3.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Authors:  Michael K Kiessling; Patrick A Oberholzer; Chandrani Mondal; Maria B Karpova; Marie C Zipser; William M Lin; Michael Girardi; Laura E Macconaill; Sarah M Kehoe; Charlie Hatton; Lars E French; Levi A Garraway; Gernot Polier; Dorothee Süss; Claus-Detlev Klemke; Peter H Krammer; Karsten Gülow; Reinhard Dummer
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

4.  Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.

Authors:  Anke K Bergmann; Sina Schneppenheim; Marc Seifert; Matthew J Betts; Andrea Haake; Cristina Lopez; Eva Maria Murga Penas; Inga Vater; Sandrine Jayne; Martin J S Dyer; Martin Schrappe; Ulrich Dührsen; Ole Ammerpohl; Robert B Russell; Ralf Küppers; Jan Dürig; Reiner Siebert
Journal:  Genes Chromosomes Cancer       Date:  2014-01-21       Impact factor: 5.006

5.  Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

Authors:  Laura Y McGirt; Peilin Jia; Devin A Baerenwald; Robert J Duszynski; Kimberly B Dahlman; John A Zic; Jeffrey P Zwerner; Donald Hucks; Utpal Dave; Zhongming Zhao; Christine M Eischen
Journal:  Blood       Date:  2015-06-16       Impact factor: 22.113

6.  Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.

Authors:  Elena Netchiporouk; Ivan V Litvinov; Linda Moreau; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.

Authors:  V H Sommer; O J Clemmensen; O Nielsen; M Wasik; P Lovato; C Brender; K W Eriksen; A Woetmann; C G Kaestel; M H Nissen; C Ropke; S Skov; N Ødum
Journal:  Leukemia       Date:  2004-07       Impact factor: 11.528

8.  PLCG1 mutations in cutaneous T-cell lymphomas.

Authors:  José P Vaqué; Gonzalo Gómez-López; Verónica Monsálvez; Ignacio Varela; Nerea Martínez; Cristina Pérez; Orlando Domínguez; Osvaldo Graña; José L Rodríguez-Peralto; Socorro M Rodríguez-Pinilla; Carmen González-Vela; Miriam Rubio-Camarillo; Esperanza Martín-Sánchez; David G Pisano; Evangelia Papadavid; Theodora Papadaki; Luis Requena; José A García-Marco; Miriam Méndez; Mariano Provencio; Mercedes Hospital; Dolores Suárez-Massa; Concepción Postigo; David San Segundo; Marcos López-Hoyos; Pablo L Ortiz-Romero; Miguel A Piris; Margarita Sánchez-Beato
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Delphine Rolland; Anagh A Sahasrabuddhe; Fuzon Chung; Nathanael G Bailey; Alexandra Schrader; Bo Li; Jun Z Li; Ayse B Ozel; Bryan L Betz; Roberto N Miranda; L Jeffrey Medeiros; Lili Zhao; Marco Herling; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

View more
  23 in total

1.  JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients.

Authors:  Matthew K Stein; Lindsay K Morris; Mike G Martin
Journal:  Pathol Oncol Res       Date:  2018-06-03       Impact factor: 3.201

2.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Authors:  Tammy Linlin Song; Maarja-Liisa Nairismägi; Yurike Laurensia; Jing-Quan Lim; Jing Tan; Zhi-Mei Li; Wan-Lu Pang; Atish Kizhakeyil; Giovani-Claresta Wijaya; Da-Chuan Huang; Sanjanaa Nagarajan; Burton Kuan-Hui Chia; Daryl Cheah; Yan-Hui Liu; Fen Zhang; Hui-Lan Rao; Tiffany Tang; Esther Kam-Yin Wong; Jin-Xin Bei; Jabed Iqbal; Nicholas-Francis Grigoropoulos; Siok-Bian Ng; Wee-Joo Chng; Bin-Tean Teh; Soo-Yong Tan; Navin Kumar Verma; Hao Fan; Soon-Thye Lim; Choon-Kiat Ong
Journal:  Blood       Date:  2018-07-27       Impact factor: 22.113

3.  Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.

Authors:  Alessandro Pileri; Claudio Agostinelli; Maurizio Sessa; Pietro Quaglino; Marco Santucci; Carlo Tomasini; Vieri Grandi; Paolo Fava; Chiara Astrua; Simona Righi; Annalisa Patrizi; Stefano A Pileri; Nicola Pimpinelli
Journal:  Virchows Arch       Date:  2017-03-20       Impact factor: 4.064

4.  JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Authors:  Sara Yumeen; Fatima N Mirza; Julia M Lewis; Amber Loren O King; Sa Rang Kim; Kacie R Carlson; Sheila R Umlauf; Yulia V Surovtseva; Francine M Foss; Michael Girardi
Journal:  Blood Adv       Date:  2020-05-26

5.  PCM1::JAK2 fusion associates with an atypical form of mycosis fungoides.

Authors:  Juan Jose Rodriguez-Sevilla; Marta Salido; Maria Rodriguez-Rivera; Blanca Sanchez-Gonzalez; Fernando Gallardo; Ramon Maria Pujol; Luis Colomo
Journal:  Virchows Arch       Date:  2022-07-04       Impact factor: 4.064

Review 6.  Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.

Authors:  William E Damsky; Jaehyuk Choi
Journal:  Curr Treat Options Oncol       Date:  2016-07

Review 7.  JAK-STAT in Early Hematopoiesis and Leukemia.

Authors:  Eirini Sofia Fasouli; Eleni Katsantoni
Journal:  Front Cell Dev Biol       Date:  2021-05-14

8.  Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Signe Spetalen; Assia Bassarova; Klaus Beiske; Francesca Micci; Sverre Heim
Journal:  Oncotarget       Date:  2017-10-10

Review 9.  Advances in the understanding and management of T-cell prolymphocytic leukemia.

Authors:  Kamel Laribi; Pierre Lemaire; Jeremy Sandrini; Alix Baugier de Materre
Journal:  Oncotarget       Date:  2017-11-01

10.  Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol.

Authors:  Minakshi Nihal; Jianqiang Wu; Connor J Stonesifer; Jay Daniels; Jaehyuk Choi; Larisa Geskin; Alain H Rook; Gary S Wood
Journal:  J Invest Dermatol       Date:  2021-08-03       Impact factor: 7.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.